General contact

Novartis Pharmaceuticals UK Limited
UK Head Office
Frimley Business Park Frimley
Camberley Surrey GU16 7SR

+44 1276 692255
+44 1276 692508
Monday - Friday,
8:30 - 17:30


Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel

+41 61 324 79 44


Novartis UK Press Office
Press Office enquiries only

+44 1276 698691

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

More information

Product Information

For enquiries contact

+44 1276 698 370

Novartis UK homepage homepage banner


Novartis receives two landmark European authorisations for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis

23 Nov 2015 Novartis announced today that the European Commission (EC) has granted authorisation for Cosentyx®​ (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor (anti-TNF) therapy.

Novartis' new heart failure medicine Entresto™ (sacubitril valsartan) recommended by CHMP for EU approval

29 Sep 2015 Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Entresto™ (sacubitril valsartan). Pending final approval by the European Commission (EC), Entresto (sacubitril valsartan), previously known as LCZ696, will be licensed for use in the UK for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction (HFrEF).

New heart failure medicine LCZ696 (sacubitril valsartan) to be available to the NHS under the Early Access to Medicines Scheme (EAMS)

2 Sep 2015 Novartis today announced that its investigational heart failure treatment LCZ696 (sacubitril valsartan) has been given a positive scientific opinion under the Medicines and Healthcare products Regulatory Agency (MHRA) Early Access to Medicines Scheme (EAMS) for patients with significant unmet medical need. This allows LCZ696 (sacubitril valsartan) to be made available to eligible patients before a final European licensing decision is made.

Top Links